Skip to main content

Specimen Collection Manual and Test Catalog

  or
  or
  or

FECAL LACTOFERRIN, EIA

Geisinger Epic Procedure Code:  LAB2267    Geisinger Epic ID:  45112

SPECIMEN COLLECTION
Specimen type: 

Fresh stool


Preferred collection container: 
Specimen required: 

1-2 ml fresh liquid, semisolid, or formed stool in a sterile cup with no preservatives


Special notes: 

Fecal samples from breast-fed infants should not be used with this assay. This test may not be appropriate for immunocompromised patients.



SPECIMEN PROCESSING
Transport temperature: 

Transport specimens to laboratory at 2-8ºC (2-25ºC is also acceptable).


Specimen stability: 

2-25ºC up to one week.


Rejection criteria: 

Specimens collected in Protofix CLR, ETM, Formalin, PVA, or SAF. Improperly labelled or collected specimens. Insufficient volume.



TEST DETAILS
Interpretation guide: 

Negative, no lactoferrin detected.


Critical values/courtesy alerts: 
Positve, lactoferrin detected.
Additional information: 

The Leuko EZ Vue test detects elevated levels of lactoferrin released from fecal leukocytes as a marker of intestinal inflammation. This test may not be appropiate in an immunocompromised patient.


CPT code(s):  83630
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.

Test includes: 

Qualitative detection of elevated levels of fecal lactoferrin


Methodology: 
Immunochromatographic Assay
Synonyms: 

WBC, Fecal WBC, Fecal leukocytes, White Blood Cells, Stool lactoferrin, fecal lactoferrin, FLEIA


Clinical significance: 

A positive test result indicates an increased level of fecal lactoferrin and warrants additional testing. Inflammation diarrheas are caused by pathogens such as Shigella, Salmonella, Camplyobacter jejunii, and Clostridium difficile. In inflammatory diarrheas fecal leukocytes are found in feces in large numbers. This test may not be appropiate for immunocompromised patients.


Doctoral Director(s): 
Donna Wolk PhD, D(ABMM)
Julie Hirschhorn, PhD, HCLD(ABB)
Review Date:  12/31/2024

Performing Locations